Page 176 - 2019_11 Resto del Mondo-web

M.C. Minnema et al.
any mortality and improved the CR rate from 20% to
46% at 6 months after auto-SCT.
Acknowledgments
The authors would like to thank all participating patients and study centers. The authors also thank the local data managers
for study coordination and collecting patients’ data, in particular the study team at the HOVON Data Center, Klaartje Nijssen and Marianne Gawlik. This investigator-sponsored trial was financially supported by the Dutch Cancer Society (KWF UU- 2010-4884) and Janssen Cilag which provided the drug borte- zomib, free of charge.
References
1. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387 (10038):2641-2654.
2. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival out- comes. J Clin Oncol. 2012;30(36):4541- 4549.
3. Gertz MA, Lacy MQ, Dispenzieri A, et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achiev- ing a complete response. Haematologica. 2007;92(10):1415-1418.
4. Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood. 2013;121(26): 5124-5130.
5. Gertz MA, Lacy MQ, Dispenzieri A, et al. Refinement in patient selection to reduce treatment-related mortality from autolo- gous stem cell transplantation in amyloido- sis. Bone Marrow Transplant. 2013;48(4): 557-561.
6. Sanchorawala V, Sun F, Quillen K, Sloan JM, Berk JL, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell trans- plantation: 20-year experience. Blood. 2015;126(20):2345-2347.
7. D'Souza A, Dispenzieri A, Wirk B, et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a center for international blood and marrow transplant research study. J Clin Oncol. 2015;33(32): 3741-3749.
8. Hazenberg BP, Croockewit A, van der Holt B, et al. Extended follow up of high-dose melphalan and autologous stem cell trans- plantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology. Haematologica. 2015;100(5):677- 682.
9. Hwa YL, Kumar SK, Gertz MA, et al. Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evalua- tion. Am J Hematol. 2016;91(10):984-988.
10. Afrough A, Saliba RM, Hamdi A, et al.
Impact of induction therapy on the outcome 20. of immunoglobulin light chain amyloidosis
after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24(11): 2197-2203.
11. Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Efficacy of borte- zomib in systemic AL amyloidosis with 21. relapsed/refractory clonal disease. Haematologica. 2008;93(2):295-298.
12. Kastritis E, Wechalekar AD, Dimopoulos
MA, et al. Bortezomib with or without dexamethasone in primary systemic (light
chain) amyloidosis. J Clin Oncol. 2010;28(6): 1031-1037. 22.
13. Reece DE, Hegenbart U, Sanchorawala V, et
al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of
a phase 1/2 study. Blood. 2011;118(4):865-
873. 23.
14. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treat-
ment response in immunoglobulin light
chain amyloidosis (AL): a consensus opinion
from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 24. 18-22 April 2004. Am J Hematol. 2005;79 (4):319-328.
15. Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light- 25. chain amyloidosis. Leukemia. 2012;26(11): 2317-2325.
16. Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early 26. markers of renal response to chemotherapy
in AL amyloidosis. Blood. 2014;124(15): 2325-2332.
17. Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac tro- 27. ponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood
stem cell transplantation. Blood.
2004;104(6):1881-1887. 28. 18. Perez-Persona E, Vidriales MB, Mateo G, et
al. New criteria to identify risk of progres-
sion in monoclonal gammopathy of uncer-
tain significance and smoldering multiple
myeloma based on multiparameter flow 29. cytometry analysis of bone marrow plasma
cells. Blood. 2007;110(7):2586-2592.
19. Palladini G, Merlini G. What is new in diag- nosis and management of light chain amy- loidosis? Blood. 2016;128(2):159-168.
Huang X, Wang Q, Chen W, et al. Induction therapy with bortezomib and dexametha- sone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized con- trolled trial. BMC Med. 2014;12:2. Sanchorawala V, Brauneis D, Shelton AC, et al. Induction therapy with bortezomib fol- lowed by bortezomib-high dose melphalan and stem cell transplantation for light chain amyloidosis: tesults of a prospective clinical trial. Biol Blood Marrow Transplant. 2015;21(8):1445-1451.
Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib- dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119(19):4391-4394.
Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dex- amethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119(19):4387-4390.
Paiva B, Vidriales MB, Perez JJ, et al. The clinical utility and prognostic value of multi- parameter flow cytometry immunopheno- typing in light-chain amyloidosis. Blood. 2011;117(13):3613-3616.
Jaccard A, Moreau P, Leblond V, et al. High- dose melphalan versus melphalan plus dexa- methasone for AL amyloidosis. N Engl J Med. 2007;357(11):1083-1093.
Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac bio- markers and serum free light chain measure- ments. J Clin Oncol. 2012;30(9):989-995. Wechalekar AD, Schonland SO, Kastritis E, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420-3427.
Madan S, Kumar SK, Dispenzieri A, et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood. 2012;119(5):1117-1122.
Cibeira MT, Sanchorawala V, Seldin DC, et al. Outcome of AL amyloidosis after high- dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood. 2011;118(16):4346- 4352.
2282
haematologica | 2019; 104(11)